Monaco Asset Management SAM lowered its holdings in Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report) by 66.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 117,188 shares of the biopharmaceutical company’s stock after selling 232,812 shares during the quarter. Monaco Asset Management SAM’s holdings in Lexicon Pharmaceuticals were worth $135,000 as of its most recent SEC filing.
Several other hedge funds have also bought and sold shares of the business. Geode Capital Management LLC grew its position in Lexicon Pharmaceuticals by 4.3% in the 4th quarter. Geode Capital Management LLC now owns 2,500,022 shares of the biopharmaceutical company’s stock valued at $2,876,000 after purchasing an additional 102,099 shares during the period. Leonteq Securities AG acquired a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at $34,000. R Squared Ltd boosted its holdings in Lexicon Pharmaceuticals by 45.3% during the 4th quarter. R Squared Ltd now owns 46,579 shares of the biopharmaceutical company’s stock worth $54,000 after acquiring an additional 14,530 shares during the last quarter. UBS Group AG boosted its holdings in Lexicon Pharmaceuticals by 752.1% during the 4th quarter. UBS Group AG now owns 3,007,237 shares of the biopharmaceutical company’s stock worth $3,458,000 after acquiring an additional 2,654,315 shares during the last quarter. Finally, Hennion & Walsh Asset Management Inc. boosted its holdings in Lexicon Pharmaceuticals by 15.7% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 901,222 shares of the biopharmaceutical company’s stock worth $1,036,000 after acquiring an additional 122,010 shares during the last quarter. Institutional investors and hedge funds own 74.70% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. Citigroup lifted their price objective on shares of Lexicon Pharmaceuticals from $2.30 to $3.10 and gave the stock a “buy” rating in a report on Monday, May 11th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, March 23rd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Lexicon Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $4.55.
Lexicon Pharmaceuticals Price Performance
LXRX opened at $2.18 on Monday. The company has a debt-to-equity ratio of 0.24, a current ratio of 18.80 and a quick ratio of 18.77. The company has a market capitalization of $968.36 million, a price-to-earnings ratio of -31.14 and a beta of 1.06. The firm’s fifty day moving average price is $1.85 and its two-hundred day moving average price is $1.55. Lexicon Pharmaceuticals, Inc. has a 1 year low of $0.62 and a 1 year high of $2.53.
Lexicon Pharmaceuticals (NASDAQ:LXRX – Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported $0.00 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.04. The firm had revenue of $21.10 million for the quarter, compared to the consensus estimate of $9.79 million. Lexicon Pharmaceuticals had a negative net margin of 37.46% and a negative return on equity of 18.64%. As a group, analysts anticipate that Lexicon Pharmaceuticals, Inc. will post -0.17 earnings per share for the current fiscal year.
Lexicon Pharmaceuticals Profile
Lexicon Pharmaceuticals, Inc is a biopharmaceutical company focused on the discovery and development of novel medicines through its proprietary genome biology platform. By leveraging large-scale gene knockout libraries, the company identifies potential therapeutic targets and advances them through preclinical and clinical development. Lexicon’s approach emphasizes the translation of genetic insights into targeted therapies for a range of human diseases.
The company’s most advanced product is telotristat ethyl (sold under the brand name XERMELO), an oral treatment approved for the management of carcinoid syndrome diarrhea in patients inadequately controlled by somatostatin analog therapy.
Featured Articles
- Five stocks we like better than Lexicon Pharmaceuticals
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Want to see what other hedge funds are holding LXRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX – Free Report).
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
